Revolutionising Individualised Dosing: The Future of Pharmaceutical Innovations?

Key Takeaways

• Swedish startup OnDosis aims to revolutionise individualised dosing in the pharmaceutical industry.
• OnDosis’ proprietary technology allows for orally administered drugs to be personalised in dose amounts, aiming to improve patient outcomes and adherence to treatment.
• Founded in 2017 by GU Ventures and Martin Olovsson, OnDosis has potential applications across multiple disease areas.

Personalisation has become a cornerstone of modern healthcare, with the understanding that individual needs vary greatly. One such company at the forefront of this trend is OnDosis. Located in Mölndal, in the Vastra Gotaland region of Sweden, this startup is all set to bring change to the pharmaceutical industry through its cutting edge technology and innovative approach to dosing individualised medication.

OnDosis’ goal is to provide ease and assurance in disease management. Their proprietary technology works by delivering flexible and personalised doses of orally taken medicines, which are formulated as micro capsules. It aims to support patients in adhering to their treatment regimen and provides a new level of convenience. Currently, they are developing products for conditions like ADHD, pain management, and organ transplant immunosuppression.

What sets OnDosis apart is looking at their unique approach to drug delivery. Traditionally, medication dosing is a one-size-fits-all process, with patients taking predefined amounts of medication. This can often lead to inefficiencies and in some cases, adverse reactions. OnDosis, however, creates a unique platform for individualised dosing. This not only ensures that patients receive exactly the dosage they need, but also allows doctors to fine-tune a patient’s treatment in a more precise manner than ever before. Furthermore, it ultimately improves healthcare outcomes and patient experiences.

The company was spun out from AstraZeneca and continues to leverage from its technology created from developmental work initiated there. Currently, it operates a network of strategic partners across all core functions including formulation and device development, intellectual property, regulatory and business development. The company continues to push the envelope in terms of what is possible with individualised dosing.

Individualising medicine and pharmaceuticals is the future of healthcare. This makes OnDosis a company to keep an eye on as it leads the way in creating innovative solutions in this arena. If its technology proves successful and is implemented in a wider scale, it has the potential to bring a significant positive impact to both patients and the entire healthcare industry.

To stay updated with what this promising startup is up to and the strides they are making in the industry, be sure to follow them on LinkedIn and check out their official website ondosis.com.